Clinical use of aromatase inhibitors (AI) in premenopausal women

Ziegler, Dominique de; Mattenberger, Christophe; Luyet, Carine; Romoscanu, Ilinca; Irion, Nicole Fournet; Bianchi‐Demicheli, Francesco

doi:10.1016/j.jsbmb.2005.04.023

Cited by 20 publications

(12 citation statements)

References 33 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AI provoke a strong decrease in estrogen levels and increase FSH levels in postmenopausal patients [110]. In premenopause, though, the inhibition of estrogen production is only temporary and the subsequent FSH increase may, in turn, stimulate follicular growth, aromatase production and restore pre-CT estradiol levels [17].…”

Section: When Are Patients With Chemotherapy-related Amenorrhea Actuamentioning

confidence: 99%

“…Instead, AI as single agents are contraindicated in premenopausal patients and in those presenting residual ovarian function [16]. In these patients, the inappropriate use of AI induces a temporary inhibition of estrogen production, leading to a feedback increase in gonadotropin levels, which, in turn, stimulate follicular growth, aromatase activity and restoration of pre-CT estradiol levels [17]. These changes in hormonal levels would be expected to reduce or abolish the efficacy of the anticancer treatment received and expose patients to further unjustified side-effects, including pain from ovarian hyperstimulation and increased risk of unplanned pregnancy [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer

Torino

Barnabei²,

Vecchis

et al. 2014

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: When Are Patients With Chemotherapy-related Amenorrhea Actuamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer

Torino

Barnabei²,

Vecchis

et al. 2014

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…It has been reported that pre/ perimenopausal women at the time of diagnosis who became amenorrheic following adjuvant CT may have received an AI as monotherapy, if they had shown FSH/E 2 levels within menopausal range (Burstein et al 2006, Smith et al 2006. The inappropriate use of AI in premenopausal women induces a temporary inhibition of estrogen production, leading to a feedback increase in gonadotropin levels, which, in turn, stimulate follicular growth, aromatase production, and restoration of pre-CT E 2 levels (de Ziegler et al 2005). These changes in hormonal levels would be expected to reduce or abolish the efficacy of the anticancer treatment received, and to expose further unjustified side effects, including pain from ovarian hyperstimulation and increased risk of unplanned pregnancy (Smith et al 2006).…”

Section: Recognizing Menopause In Women Affected By Ebc and Ciamentioning

confidence: 99%

Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer

Torino¹,

Barnabei²,

Vecchis³

et al. 2012

Endocrine-Related Cancer

View full text Add to dashboard Cite

Cytotoxic anticancer treatment may induce amenorrhea or menopause to a variable extent. These side effects may not only impair or impede fertility but also cause sexual dysfunction, bone loss, and menopausal symptoms, with a strikingly negative effect on quality of life in many women. Aromatase inhibitors (AIs) are a recommended adjuvant endocrine treatment option in postmenopausal patients affected by early breast cancer (EBC) but are contraindicated in premenopausal women and in those with residual ovarian function. Women over 40 years of age with chemotherapy-induced amenorrhea (CIA) and routine hormonal levels consistent with menopause may receive an AI as adjuvant endocrine treatment. For these women, the tools available to identify menopause do not appear to be completely reliable. This review focused on the pathophysiology of ovarian toxicity induced by cytotoxic agents and on potentially useful methods to diagnose chemotherapy-induced menopause in patients treated with adjuvant chemotherapy for endocrine-responsive EBC. Moreover, practical approaches are proposed to distinguish true menopausal women, who would benefit from AIs, from those with transient or persistent CIA.

show abstract

“…Treatment of endometriosis and uterine fibroids represent additional areas of application for aromatase inhibitors in premenopausal women (Ziegler et al, 2005).…”

Section: Case Reportmentioning

confidence: 99%

Microtia After Ovulation Induction with Letrozole

Al-Sunaidi¹

2011

American Journal of Pharmacology and Toxicology

View full text Add to dashboard Cite

Problem statement: Letrozole gained lots of interest over the past decayed as a medication for ovulation induction to achieve monofollicular results, although few retrospective analysis of congenital anolamalies detected for babies who were conceived via this medication; the dispute still exist and the need for large multicenter studies are needed to resolve this issue. Approach: In the current report; we report a case of microtia who was conceived as a result of ovulation induction with letrozole. Results: This case draws our attention to the safety of letrozole as an ovulation induction medication. Conclusion: The reported case here mandates that babies delivered as a consequence of ovulation induction with aromatase inhibitors should be examined antenatal and postnatally for possible congenital anomalies and to be reported to settle the argument weather theses medications are safe or not in term of ovulation induction.

show abstract

Clinical use of aromatase inhibitors (AI) in premenopausal women

Cited by 20 publications

References 33 publications

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer

Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer

Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer

Microtia After Ovulation Induction with Letrozole

Contact Info

Product

Resources

About